Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | DRMA | Common Stock | Award | $0 | +30.2K | +66.18% | $0.00 | 75.7K | Oct 6, 2022 | Direct | F1 |
holding | DRMA | Common Stock | 12.2K | Oct 6, 2022 | By Hale Trading Company L.P. | F2 | |||||
holding | DRMA | Common Stock | 35.7K | Oct 6, 2022 | By Hale Family Trust | ||||||
holding | DRMA | Common Stock | 533K | Oct 6, 2022 | By Hale BioPharma Ventures LLC | F2 |
Id | Content |
---|---|
F1 | On October 6, 2022, the Reporting Person was granted 30,155 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan. |
F2 | Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |